semaglutide cardiovascular outcomes news Improves in Patients With History of Coronary Artery Bypass Graft and Obesity semaglutide cardiovascular outcomes news 2025

During this period, focusing on healthy habits like balanced eating and regular physical activity is essential for long-term success

It binds to toxins, heavy metals, and metabolic waste products so they can be safely eliminated

I sometimes joke that I'm a walking GLP-1 advertisement

If semaglutide fatigue is limiting your activity, even gentle movement is better than none

ATTAIN-1 (NCT05869903) was a Phase III, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of orforglipron at various doses to placebo in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, who did not have diabetes